

Production, Quality Control, and Biodistribution Studies of ^{141}Ce -Edtmp as a Potential Bone Pain Palliation Agent

Authors : Fatemeh Soltani, Simindokht Shirvani Arani, Ali Bahrami Samani, Mahdi Sadeghi, Kamal Yavari

Abstract : Cerium-141 [$T_{1/2} = 32.501$ days, $E_{\beta}(\text{max}) = 0.580$ (29.8%) and 0.435 (70.2%) MeV, $E_{\gamma}=145.44$ (48.2%) keV] possesses radionuclidic properties suitable for use in palliative therapy of bone metastases. ^{141}Ce also has gamma energy of 145.44 keV, which resembles that of $^{99\text{m}}\text{Tc}$. Therefore, the energy window is adjustable on the Tc-99m energy because of imaging studies. ^{141}Ce can be produced through a relatively easy route that involves thermal neutron bombardment on natural CeO_2 in medium flux research reactors ($4\text{-}5 \times 10^{13}$ neutrons/cm $^2 \cdot$ s). The requirement for an enriched target does not arise. Ethylenediamine tetramethylene phosphonic acid (EDTMP) was synthesized and radiolabeled with ^{141}Ce . Complexation parameters were optimized to achieve maximum yields (>99%). The radiochemical purity of ^{141}Ce -EDTMP was evaluated by radio-thin layer chromatography. The stability of the prepared formulation was monitored for one week at room temperature, and results showed that the preparation was stable during this period (>99%). Biodistribution studies of the complexes carried out in wild-type rats exhibited significant bone uptake with rapid clearance from blood. The properties of produced ^{141}Ce -EDTMP suggest applying a new efficient bone pain palliative therapeutic agent to overcome metastatic bone pains.

Keywords : bone pain palliative, cerium-141, EDTMP, radiopharmaceutical

Conference Title : ICRR 2015 : International Conference on Radiopharmacy and Radiopharmaceuticals

Conference Location : Madrid, Spain

Conference Dates : March 26-27, 2015